# A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

> **NCT06115642** · PHASE1 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 340 (estimated)

## Conditions studied

- Advanced/Metastatic Malignant Solid Tumors

## Interventions

- **DRUG:** HLX43
- **DRUG:** HLX10

## Key facts

- **NCT ID:** NCT06115642
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-24
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06115642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06115642, "A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06115642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*